{"id":"7b613ea1-04e7-5c2f-b954-5a2d5d2a3428","stable_key":"ff370329-68a3-573d-96ee-597de78a3967:api-glucuronide-ap1","predicate":"decreases_in_recorded_comparison","statement":"The glucuronide reduced AP-1/c-Jun activation, p38/ERK phosphorylation and iNOS/COX-2 expression in the reported macrophage model.","claim_class":"observational","status":"source_recorded","evidence_grade":"ungraded","direction":"negative","is_public":true,"mechanism_event_id":"4889b0c4-0d33-568b-97ff-595f0bf3c506","mechanism_event_label":"The glucuronide reduced AP-1/c-Jun activation, p38/ERK phosphorylation and iNOS/COX-2 expression in the reported macrophage model.","subject":{"id":"353de06b-4efb-5810-a466-8f1056a30ecb","slug":"apigenin-7-glucuronide","display_name":"Apigenin 7-O-glucuronide","entity_type_key":"small_molecule"},"object":{"id":"a869e1f0-f971-5f5e-b028-adeaa3dcb4b4","slug":"mouse-apigluc-ap1","display_name":"AP-1 signaling in the apigenin-glucuronide macrophage study","entity_type_key":"cellular_process"},"evidence_count":1,"mechanism_event":{"id":"4889b0c4-0d33-568b-97ff-595f0bf3c506","stable_key":"ff370329-68a3-573d-96ee-597de78a3967:api-glucuronide-ap1-event","event_type":"experimental_observation","label":"The glucuronide reduced AP-1/c-Jun activation, p38/ERK phosphorylation and iNOS/COX-2 expression in the reported macrophage model.","description":"### api-glucuronide-ap1\n\nThe glucuronide reduced AP-1/c-Jun activation, p38/ERK phosphorylation and iNOS/COX-2 expression in the reported macrophage model.\nSignaling and expression observations are not direct binding measurements.\nModel and exposure: LPS-stimulated mouse RAW264.7 cells; primary abstract.\nLimitations: Limited to the recorded preparation, model, exposure and endpoint. Does not establish a human dietary deficiency, clinical benefit or unique molecular mediation.\nReference: Apigenin-7-O-β-D-glucuronide inhibits LPS-induced inflammation through the inactivation of AP-1 and MAPK signaling pathways in RAW 264.7 macrophages and protects mice against endotoxin shock. | 2016 | https://pubmed.ncbi.nlm.nih.gov/26750400/ | https://doi.org/10.1039/c5fo01212k | Access: Indexed primary abstract/metadata only; unextracted doses, figures and methods remain unknown.","status":"provisional","compartment":null,"participants":[{"entity":{"id":"353de06b-4efb-5810-a466-8f1056a30ecb","slug":"apigenin-7-glucuronide","display_name":"Apigenin 7-O-glucuronide","entity_type_key":"small_molecule"},"role":"tested factor","stoichiometry":null,"state_label":"Glucuronide plus LPS","sequence_order":0,"notes":""},{"entity":{"id":"a869e1f0-f971-5f5e-b028-adeaa3dcb4b4","slug":"mouse-apigluc-ap1","display_name":"AP-1 signaling in the apigenin-glucuronide macrophage study","entity_type_key":"cellular_process"},"role":"measured outcome","stoichiometry":null,"state_label":"decrease","sequence_order":1,"notes":""}]},"contexts":[{"dimension":"evidence_access","value_text":"Indexed primary abstract/metadata only; unextracted doses, figures and methods remain unknown.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"experimental_condition","value_text":"Glucuronide plus LPS","comparator":"LPS alone","unit":null,"notes":"Condition belongs to the full experimental contrast; do not separate a joint intervention.","entity":{"slug":"apigenin-7-glucuronide","display_name":"Apigenin 7-O-glucuronide","entity_type_key":"small_molecule"}},{"dimension":"experimental_condition","value_text":"LPS challenge","comparator":"LPS alone","unit":null,"notes":"Condition belongs to the full experimental contrast; do not separate a joint intervention.","entity":{"slug":"lipopolysaccharide","display_name":"Lipopolysaccharide","entity_type_key":"chemical_species"}},{"dimension":"experimental_contrast","value_text":"{\"intervention\": \"Glucuronide plus LPS\", \"comparator\": \"LPS alone\", \"endpoint\": \"The glucuronide reduced AP-1/c-Jun activation, p38/ERK phosphorylation and iNOS/COX-2 expression in the reported macrophage model.\", \"effect_direction\": \"decrease\", \"combination\": \"joint\", \"conditions\": [{\"entity_slug\": \"apigenin-7-glucuronide\", \"state\": \"Glucuronide plus LPS\"}, {\"entity_slug\": \"lipopolysaccharide\", \"state\": \"LPS challenge\"}]}","comparator":null,"unit":null,"notes":"Explicit extracted experimental comparison; recorded from source.","entity":null},{"dimension":"experimental_model","value_text":"LPS-stimulated mouse RAW264.7 cells; primary abstract.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"interpretation_status","value_text":"Recorded from source with stated access limits; ungraded, not independent replication.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"limitations","value_text":"Limited to the recorded preparation, model, exposure and endpoint. Does not establish a human dietary deficiency, clinical benefit or unique molecular mediation.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"nutrient_topic","value_text":"Apigenin collection; exact intervention and molecular form govern interpretation.","comparator":null,"unit":null,"notes":"","entity":{"slug":"apigenin","display_name":"Apigenin","entity_type_key":"small_molecule"}},{"dimension":"plain_language","value_text":"The glucuronide reduced AP-1/c-Jun activation, p38/ERK phosphorylation and iNOS/COX-2 expression in the reported macrophage model.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"primary_references","value_text":"Apigenin-7-O-β-D-glucuronide inhibits LPS-induced inflammation through the inactivation of AP-1 and MAPK signaling pathways in RAW 264.7 macrophages and protects mice against endotoxin shock. | https://pubmed.ncbi.nlm.nih.gov/26750400/ | https://doi.org/10.1039/c5fo01212k","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"source_locator","value_text":"Reviewed reference api-glucuronide-ap1; Signaling and expression observations are not direct binding measurements.","comparator":null,"unit":null,"notes":"","entity":null}],"evidence":[{"id":"ab7d46d8-2d67-5c5e-9809-464194605b98","evidence_kind":"source_excerpt","locator":"Lines 138-144","start_line":138,"end_line":144,"excerpt":"### api-glucuronide-ap1\n\nThe glucuronide reduced AP-1/c-Jun activation, p38/ERK phosphorylation and iNOS/COX-2 expression in the reported macrophage model.\nSignaling and expression observations are not direct binding measurements.\nModel and exposure: LPS-stimulated mouse RAW264.7 cells; primary abstract.\nLimitations: Limited to the recorded preparation, model, exposure and endpoint. Does not establish a human dietary deficiency, clinical benefit or unique molecular mediation.\nReference: Apigenin-7-O-β-D-glucuronide inhibits LPS-induced inflammation through the inactivation of AP-1 and MAPK signaling pathways in RAW 264.7 macrophages and protects mice against endotoxin shock. | 2016 | https://pubmed.ncbi.nlm.nih.gov/26750400/ | https://doi.org/10.1039/c5fo01212k | Access: Indexed primary abstract/metadata only; unextracted doses, figures and methods remain unknown.","model_system":"LPS-stimulated mouse RAW264.7 cells; primary abstract.","directness":"reported_statement","verification_status":"source_recorded","notes":"Original paraphrase in the retained reviewed reference, not a verbatim primary-paper quotation. Access level is explicit.","relationship":"supports","weight":1.0,"link_notes":"","source":{"id":"54eac90b-add1-5f56-9036-d900307c5697","stable_key":"import-ff370329-68a3-573d-96ee-597de78a3967","title":"Apigenin: detailed mechanisms of action (reviewed 10 October 2026)","document_type":"imported_text","citation_label":"AI-assisted original curation of primary studies; claim-local access and experimental limitations stated. Includes original-draft correction history. No independent replication claimed.","file_path":"","sha256":"ede6e5c6b91d66b66844f2ff667a7f8303d9ac1281f15dc09db703f7de4da942","revision_id":"b41a39a2-0197-549c-97a5-1765e6696931","review_status":"source_recorded","notes":""}}],"relations":[],"conflicts":[],"corrections":[],"research":null}